Biosimilars Market by Product, Manufacturing & Indication and Region – Global Forecast to 2025

NEXT STORY
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer
PREV STORY
OpGen Announces Shareholder Approval for Business Combination with Curetis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

author_avatar
NASDAQ Market News

Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary ...

author_avatar
NASDAQ Market News

Alignment Healthcare’s AVA® Technology Platform Powers More Than 1 Million Personalized Care Interactions to Date

author_avatar
NASDAQ Market News